Interprotein

Interprotein operates in the biotechnology sector, specializing in drug discovery with a focus on protein-protein interactions (PPIs). The company serves pharmaceutical and biotech firms by providing highly active modulators for PPI targets through its proprietary technologies. Interprotein's core offerings include INTENDD, a structure-based drug discovery platform for small molecules, and a library of helix-loop-helix peptides that have shown near 100% success in identifying strong binders. The business model revolves around licensing its technology and providing drug discovery services, generating revenue through partnerships and collaborations. Interprotein aims to revolutionize the drug discovery process by targeting the vast number of druggable PPIs, which have been challenging to exploit with traditional methods. The company leverages its expertise in PPI interfaces to create novel therapeutic compounds, addressing the growing demand for innovative solutions in an increasingly difficult R&D environment.

Keywords: drug discovery, protein-protein interactions, PPI modulators, INTENDD, helix-loop-helix peptides, biotechnology, pharmaceutical, therapeutic compounds, structure-based drug design, AI-based drug discovery.